title: Antigen-specific T cells for the treatment of infections after transplantation.
abstract: Considerable progress has been made in our understanding of the immunobiology of infections in immunocompromised hosts. Insights derived from animal model and human studies have provided the rationale for investigating immunotherapy with alphabeta+ T cells to restore responses considered essential for protective immunity to cytomegalovirus and Epstein-Barr virus. Future studies will address the role of adoptive immunotherapy in the prevention and treatment of adenovirus and invasive fungal infection. The use of genetically modified T cells has already been evaluated clinically and offers the potential for improving safety and efficacy and removing obstacles to successful immunotherapy. Although these studies are in the early stages and present considerable technical challenges, the results suggest that cellular immunotherapy will be a fruitful area for investigation in future years.
authors.affiliation: Medizinische Klinik und Poliklinik, Abteilung II, Eberhard-Karls-Universität Tübingen, Germany. hermann.einsele@med.uni-tuebingen.de
authors.forename: Hermann
authors.initials: H
authors.lastname: Einsele
mesh_terms: D000257:Adenoviridae Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D000260:Adenoviruses, Human / Q000276:immunology; D000818:Animals; D000946:Antigens, Fungal / Q000276:immunology; D000956:Antigens, Viral / Q000276:immunology; D001228:Aspergillosis / Q000517:prevention & control / Q000628:therapy; D001230:Aspergillus / Q000276:immunology; D018414:CD8-Positive T-Lymphocytes / Q000276:immunology / Q000637:transplantation*; D002176:Candida albicans / Q000276:immunology; D002177:Candidiasis / Q000517:prevention & control / Q000628:therapy; D003587:Cytomegalovirus / Q000276:immunology; D003586:Cytomegalovirus Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D020031:Epstein-Barr Virus Infections / Q000209:etiology / Q000517:prevention & control / Q000628:therapy; D015316:Genetic Therapy; D015789:HLA-A2 Antigen / Q000276:immunology; D004854:Herpesvirus 4, Human / Q000276:immunology; D006801:Humans; D007111:Immunity, Cellular; D016867:Immunocompromised Host; D016219:Immunotherapy, Adoptive; D008232:Lymphoproliferative Disorders / Q000209:etiology / Q000517:prevention & control / Q000628:therapy / Q000821:virology; D051379:Mice; D011183:Postoperative Complications / Q000276:immunology / Q000628:therapy*; D016693:Receptors, Antigen, T-Cell, alpha-beta / Q000276:immunology; D016176:T-Lymphocyte Subsets / Q000276:immunology / Q000637:transplantation*; D014180:Transplantation; D014777:Virus Diseases / Q000209:etiology / Q000517:prevention & control / Q000628:therapy*
chemical_list: D000946:Antigens, Fungal; D000956:Antigens, Viral; D015789:HLA-A2 Antigen; D016693:Receptors, Antigen, T-Cell, alpha-beta